MX2015005632A - Sales de amina de laquinimod. - Google Patents
Sales de amina de laquinimod.Info
- Publication number
- MX2015005632A MX2015005632A MX2015005632A MX2015005632A MX2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A
- Authority
- MX
- Mexico
- Prior art keywords
- laquinimod
- amine salts
- lysine
- meglumine
- monoethanolamine
- Prior art date
Links
- 229960004577 laquinimod Drugs 0.000 title abstract 6
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical class OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 5
- -1 Amine salts Chemical class 0.000 title abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 abstract 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract 1
- 235000019766 L-Lysine Nutrition 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 229940075419 choline hydroxide Drugs 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Electric Double-Layer Capacitors Or The Like (AREA)
- Cosmetics (AREA)
- Epidemiology (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723495P | 2012-11-07 | 2012-11-07 | |
| PCT/US2013/067686 WO2014074381A1 (en) | 2012-11-07 | 2013-10-31 | Amine salts of laquinimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005632A true MX2015005632A (es) | 2016-02-05 |
Family
ID=50622908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005632A MX2015005632A (es) | 2012-11-07 | 2013-10-31 | Sales de amina de laquinimod. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8975279B2 (OSRAM) |
| EP (1) | EP2916915A4 (OSRAM) |
| JP (1) | JP2015535287A (OSRAM) |
| KR (1) | KR20150091077A (OSRAM) |
| CN (1) | CN104955522A (OSRAM) |
| AR (1) | AR093335A1 (OSRAM) |
| AU (1) | AU2013341506A1 (OSRAM) |
| BR (1) | BR112015010193A2 (OSRAM) |
| CA (1) | CA2890194A1 (OSRAM) |
| EA (1) | EA201590788A1 (OSRAM) |
| HK (2) | HK1215210A1 (OSRAM) |
| IL (1) | IL238535A0 (OSRAM) |
| MX (1) | MX2015005632A (OSRAM) |
| TW (1) | TW201422588A (OSRAM) |
| WO (1) | WO2014074381A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AU2013221304B2 (en) | 2012-02-16 | 2017-12-21 | Teva Pharmaceutical Industries Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| JP2017514824A (ja) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| EP3274053A4 (en) | 2015-03-23 | 2018-12-05 | The Brigham and Women's Hospital, Inc. | Tolerogenic nanoparticles for treating diabetes mellitus |
| EP3829557A1 (en) | 2018-08-03 | 2021-06-09 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Biocompatible tolerogenic nanoparticles |
| US20220031628A1 (en) | 2018-11-27 | 2022-02-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nanoparticles for preparing regulatory b cells |
| KR20210124855A (ko) | 2020-04-07 | 2021-10-15 | 주식회사 엘에스파마 | 고미가 차폐된 디클로페낙을 함유하는 약제학적 조성물 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| YU86001A (sh) | 1999-06-07 | 2004-07-15 | Altana Pharma Ag. | Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini |
| PL199781B1 (pl) | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| AU2003300692A1 (en) | 2003-10-30 | 2005-05-19 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
| PT1937642E (pt) | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| BRPI0708902A2 (pt) | 2006-03-16 | 2011-06-14 | Genentech Inc | mÉtodos de tratar lupus usando anticorpos cd4 |
| NZ573846A (en) | 2006-06-12 | 2012-01-12 | Teva Pharma | Stable laquinimod preparations |
| MX2009001788A (es) | 2006-08-17 | 2009-09-23 | Univ Chicago | Tratamiento de enfermedades inflamatorias. |
| US20100260716A1 (en) | 2007-10-23 | 2010-10-14 | Ucb Pharma Gmbh | Compounds for treating demyelination conditions |
| EP2682120B1 (en) | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2010001257A2 (en) * | 2008-07-01 | 2010-01-07 | Actavis Group Ptc Ehf | Novel solid state forms of laquinimod and its sodium salt |
| WO2010028015A2 (en) * | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| US20100322900A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| BR112012002124A2 (pt) | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| DK2467372T3 (en) | 2009-08-10 | 2016-08-22 | Teva Pharma | TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| BR112012022187A2 (pt) | 2010-03-03 | 2015-09-22 | Teva Pharma | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato |
| KR20130036217A (ko) | 2010-03-03 | 2013-04-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 관절염의 치료 |
| JP5934202B2 (ja) | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| KR20130092558A (ko) | 2010-07-09 | 2013-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도 |
| EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| MX2013006464A (es) | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| EP2736335A4 (en) | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
| WO2013016686A1 (en) | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AU2013221304B2 (en) | 2012-02-16 | 2017-12-21 | Teva Pharmaceutical Industries Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201347762A (zh) | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
| TW201350467A (zh) * | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| UY34896A (es) | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
-
2013
- 2013-10-31 EA EA201590788A patent/EA201590788A1/ru unknown
- 2013-10-31 HK HK16103249.5A patent/HK1215210A1/zh unknown
- 2013-10-31 AU AU2013341506A patent/AU2013341506A1/en not_active Abandoned
- 2013-10-31 JP JP2015540779A patent/JP2015535287A/ja active Pending
- 2013-10-31 KR KR1020157014911A patent/KR20150091077A/ko not_active Withdrawn
- 2013-10-31 US US14/068,599 patent/US8975279B2/en not_active Expired - Fee Related
- 2013-10-31 BR BR112015010193A patent/BR112015010193A2/pt active Search and Examination
- 2013-10-31 CA CA2890194A patent/CA2890194A1/en not_active Abandoned
- 2013-10-31 MX MX2015005632A patent/MX2015005632A/es unknown
- 2013-10-31 CN CN201380058339.0A patent/CN104955522A/zh active Pending
- 2013-10-31 EP EP13852663.7A patent/EP2916915A4/en not_active Withdrawn
- 2013-10-31 HK HK16100794.0A patent/HK1212936A1/zh unknown
- 2013-10-31 WO PCT/US2013/067686 patent/WO2014074381A1/en not_active Ceased
- 2013-11-01 AR ARP130104013A patent/AR093335A1/es unknown
- 2013-11-05 TW TW102140149A patent/TW201422588A/zh unknown
-
2015
- 2015-04-30 IL IL238535A patent/IL238535A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201590788A1 (ru) | 2015-12-30 |
| HK1212936A1 (zh) | 2016-06-24 |
| US8975279B2 (en) | 2015-03-10 |
| AR093335A1 (es) | 2015-06-03 |
| CA2890194A1 (en) | 2014-05-15 |
| IL238535A0 (en) | 2015-06-30 |
| EP2916915A4 (en) | 2016-06-22 |
| CN104955522A (zh) | 2015-09-30 |
| AU2013341506A1 (en) | 2015-06-04 |
| EP2916915A1 (en) | 2015-09-16 |
| US20140128430A1 (en) | 2014-05-08 |
| KR20150091077A (ko) | 2015-08-07 |
| TW201422588A (zh) | 2014-06-16 |
| BR112015010193A2 (pt) | 2017-07-11 |
| WO2014074381A1 (en) | 2014-05-15 |
| JP2015535287A (ja) | 2015-12-10 |
| HK1215210A1 (zh) | 2016-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005632A (es) | Sales de amina de laquinimod. | |
| IL242278A0 (en) | Compounds 4)-n-fluoro-2-methoxy-5-nitrophenyl)pyrimidine-2-converted amine and their salts | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| DK2915804T3 (da) | Nyt aminderivat eller salt deraf som TNF-alpha-inhibitorer | |
| CR20140306A (es) | Fluormetil -5,6-dihidro-4h-[1,3] oxazinas | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| BR112013007821A2 (pt) | método para a preparação de uma composição de concentrado aquoso de glifosato contendo mistura de sais de amina | |
| PH12016502229A1 (en) | Process for preparing phosphorus-containing cyanohydrins | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| CR20140495A (es) | 5-amino[1,4]thiazines como inhibidores de bace1 | |
| MY183123A (en) | Synthesis of copanlisib and its di hydrochloride salt | |
| IN2014DN07996A (OSRAM) | ||
| UY34553A (es) | Procedimiento de preparación de la sal de l-arginina de perindoprilo | |
| IN2014DN06192A (OSRAM) | ||
| BR112018012325A2 (pt) | métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída | |
| MX2015005739A (es) | Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2. | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| IN2013MU01501A (OSRAM) | ||
| GB201611609D0 (en) | Valsartan amine salts | |
| GB201611608D0 (en) | Valsartan amine salts | |
| UA94667U (uk) | Заміщені [2-(3-r-1h-[1,2,4]триазол-5-іл)феніл]аміни, що проявляють гіпоглікемічну активність | |
| UA86566U (en) | N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof | |
| GB201611641D0 (en) | Iosartan amine salts | |
| UA87695U (uk) | Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид, що має інотропну активність |